Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
R&D channel feed
Pfizer terminates an early-stage STING agonist trial
2 months ago
Pharma
Amgen reports more Uplizna data in myasthenia gravis ahead of FDA filing
2 months ago
Pharma
#CROI25: Merck’s troubled HIV drug heads to regulators; ViiV seeks longer-acting HIV treatment
2 months ago
Ono licenses rare blood disease drug from Ionis for $280M upfront
2 months ago
Deals
Updated: Zealand partners with Roche on its amylin analog in a deal worth up to $5.3B
2 months ago
Deals
Gilead plans to skip from Phase 1 to Phase 3 with once-yearly HIV prevention drug
2 months ago
Arvinas, Pfizer’s PROTAC data fall short of hype in breast cancer
2 months ago
Beam shares promising first clinical data on gene editing treatment for a lung and liver disease
2 months ago
Cell/Gene Tx
#AAD25: What you need to know from Amgen, Bristol Myers, J&J and more
2 months ago
Pharma
Exclusive: FDA blocks drug and device reviewers from taking HHS' buyout offer
2 months ago
Mired in low expectations, Novo braces for upcoming CagriSema head-to-head trial
2 months ago
J&J, Protagonist outline first IBD win for oral IL-23 with $5B+ sales potential
2 months ago
Trevi’s mid-stage chronic cough data meet ‘home run’ scenario, stock soars
2 months ago
Arrowhead reveals small batch of open-label data for 'non-core' kidney drug
2 months ago
Novo Nordisk’s CagriSema shows 15.7% weight loss in second pivotal trial
2 months ago
Mineralys’ Phase 3 blood pressure pill data support potential FDA approval
2 months ago
Pharma
Roche launches new research center with Harvard in Boston area
2 months ago
People
J&J axes Phase 3 depression program due to ‘insufficient efficacy’ shortly after Neumora’s study fail
2 months ago
Pharma
Novo Nordisk’s rare disease ‘company within a company’ has an open goal in sickle cell
2 months ago
Luxa's stem cell therapy for dry AMD shows early promise
2 months ago
Cell/Gene Tx
Denali stops some work on ALS drug after analysis showed no impact on key biomarker
2 months ago
Novo Nordisk looks into starting GLP-1 drug trials for addiction
2 months ago
ITM reports more Phase 3 radiopharma data in challenge to Novartis’ Lutathera
2 months ago
FDA puts BioNTech’s malaria vaccine on clinical hold
2 months ago
FDA+
First page
Previous page
5
6
7
8
9
10
11
Next page
Last page